



## Agile Therapeutics to Participate in Upcoming March Investor Events

March 11, 2022

PRINCETON, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will participate in two upcoming investor conferences, including a live panel discussion on drug development in Women's Health.

- **Oppenheimer's 32<sup>nd</sup> Annual Virtual Healthcare Conference**
  - Fireside Chat
    - Thursday, March 17, 2022 at 2:00 p.m. ET
  
- **Maxim Group and M-Vest 2022 Virtual Growth Conference**
  - *Advances in Women's Health, from Clinical to Commercial* Live Panel Discussion
    - Monday, March 28, 2022 at 3:00 p.m. ET

Links and webcast information for each conference can be found on the Investors section of the Agile Therapeutics website at <https://ir.agiletherapeutics.com/events-and-presentations>. Each archived webcast will be available for 30 days.

### **About Agile Therapeutics, Inc.**

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla<sup>®</sup>, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion<sup>®</sup>, which is designed to allow drug delivery through the skin. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com). The Company may occasionally disseminate material, nonpublic information on the Company's website.

Contact: Matt Riley Head of Investor Relations & Corporate Communications [mriley@agiletherapeutics.com](mailto:mriley@agiletherapeutics.com)